INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 187 filers reported holding INOVIO PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.11 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $29 | -95.9% | 64,715 | -92.5% | 0.00% | – |
Q1 2023 | $705 | -66.6% | 858,782 | -36.6% | 0.00% | -100.0% |
Q4 2022 | $2,112 | -99.9% | 1,353,614 | +17.0% | 0.00% | -50.0% |
Q3 2022 | $1,995,000 | +10400.0% | 1,156,481 | +10382.0% | 0.00% | – |
Q2 2022 | $19,000 | -84.9% | 11,033 | -68.8% | 0.00% | – |
Q1 2022 | $126,000 | -95.0% | 35,386 | -93.0% | 0.00% | – |
Q4 2021 | $2,504,000 | +309.8% | 501,938 | +488.5% | 0.00% | – |
Q3 2021 | $611,000 | +60.8% | 85,291 | +107.7% | 0.00% | – |
Q2 2021 | $380,000 | -73.8% | 41,058 | -73.7% | 0.00% | -100.0% |
Q1 2021 | $1,448,000 | -23.2% | 156,026 | -26.8% | 0.00% | 0.0% |
Q4 2020 | $1,886,000 | -50.6% | 213,081 | -35.2% | 0.00% | -50.0% |
Q3 2020 | $3,816,000 | -55.8% | 329,082 | +2.7% | 0.00% | -66.7% |
Q2 2020 | $8,635,000 | +501.3% | 320,375 | +66.0% | 0.01% | +500.0% |
Q1 2020 | $1,436,000 | +369.3% | 193,029 | +108.0% | 0.00% | – |
Q4 2019 | $306,000 | +157.1% | 92,782 | +60.5% | 0.00% | – |
Q3 2019 | $119,000 | -38.0% | 57,803 | -11.7% | 0.00% | – |
Q2 2019 | $192,000 | +108.7% | 65,445 | +166.4% | 0.00% | – |
Q1 2019 | $92,000 | -67.8% | 24,563 | -65.6% | 0.00% | – |
Q4 2018 | $286,000 | -33.3% | 71,479 | -7.3% | 0.00% | – |
Q3 2018 | $429,000 | +921.4% | 77,098 | +615.9% | 0.00% | – |
Q2 2018 | $42,000 | -66.4% | 10,770 | -59.4% | 0.00% | – |
Q1 2018 | $125,000 | -61.7% | 26,528 | -66.4% | 0.00% | – |
Q4 2017 | $326,000 | +143.3% | 79,064 | +276.0% | 0.00% | – |
Q3 2017 | $134,000 | -17.8% | 21,028 | +1.1% | 0.00% | – |
Q2 2017 | $163,000 | +805.6% | 20,790 | +656.6% | 0.00% | – |
Q1 2017 | $18,000 | -57.1% | 2,748 | -54.2% | 0.00% | – |
Q4 2016 | $42,000 | -73.8% | 6,003 | -64.9% | 0.00% | – |
Q3 2016 | $160,000 | +7900.0% | 17,088 | +9340.9% | 0.00% | – |
Q2 2016 | $2,000 | -95.1% | 181 | -96.5% | 0.00% | – |
Q1 2016 | $41,000 | +720.0% | 5,128 | +428.7% | 0.00% | – |
Q4 2015 | $5,000 | -98.3% | 970 | -98.4% | 0.00% | – |
Q3 2015 | $298,000 | +2383.3% | 59,220 | +3995.4% | 0.00% | – |
Q2 2015 | $12,000 | -61.3% | 1,446 | -62.8% | 0.00% | – |
Q1 2015 | $31,000 | -38.0% | 3,889 | -30.4% | 0.00% | – |
Q4 2014 | $50,000 | -23.1% | 5,586 | -22.3% | 0.00% | – |
Q3 2014 | $65,000 | +364.3% | 7,186 | +406.8% | 0.00% | – |
Q2 2014 | $14,000 | – | 1,418 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
Beck Bode, LLC | 41,218 | $33,799 | 0.01% |